Sutro Biopharma Secures $36,500,000 Series C Round

  • Feed Type
  • Date
    11/17/2010
  • Company Name
    Sutro Biopharma
  • Mailing Address
    310 Utah Ave South San Francisco, CA 94080
  • Company Description
    Sutro Biopharma, Inc. is a biopharmaceutical company that uses its patented OCFS protein synthesis technology to develop next-generation protein therapeutics for the treatment of human disease.
    This commercially scalable technology overcomes important limitations associated with mammalian, yeast, and bacterial systems and allows for faster screening and selection of product candidates without the need to develop cell lines.
  • Website
    http://www.sutrobio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $36,500,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    This financing will support the company’s ongoing development of novel biotherapeutics with superior pharmaceutical properties and advance the company’s biochemical protein synthesis platform to meet current Good Manufacturing Practice (cGMP) standards.
  • M&A Terms
  • Venture Investor
    Skyline Ventures
  • Venture Investor
    Lilly Ventures
  • Venture Investor
    Amgen Ventures
  • Venture Investor
    SV Life Sciences
  • Venture Investor
    Alta Partners

By posting a comment, you agree to our terms and conditions.